Treatment of Mpox with Suspected Tecovirimat Resistance in Immunocompromised Patient, United States, 2022
Caitlin A. Contag
, Leah Mische, Isabel Fong, Abraar Karan, Akanksha Vaidya, David W. McCormick, William Bower, Jill K. Hacker, Kelly Johnson, Perla SanJuan, Linda Crebbin, Caroline Temmins, Harleen Sahni, Yael Bogler, Joseph D. Cooper, and Supriya Narasimhan
Author affiliations: Stanford University School of Medicine, Stanford, California, USA (C.A. Contag, L. Mische, A. Karan); Santa Clara Valley Medical Center, San Jose, California, USA (I. Fong, C. Temmins, H. Sahni, Y. Bogler, J.D. Cooper, S. Narasimhan); County of Santa Clara Public Health Department, Santa Clara, California, USA (A. Vaidya, P. SanJuan); Centers for Disease Control and Prevention. Atlanta, Georgia, USA (D.W. McCormick, W. Bower); California Department of Public Health. Richmond, California, USA (J.K. Hacker, K. Johnson, L. Crebbin); University of California, San Francisco, California, USA (K. Johnson, P. SanJuan)
Main Article
Figure 2
Figure 2. Visual timeline of facial lesions (top) and left plantar lesions (bottom) of immunocompromised patient with mpox, California, USA, 2022. Treatment received is indicated between images. IV, intravenous.
Main Article
Page created: October 19, 2023
Page updated: November 18, 2023
Page reviewed: November 18, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.